Corcept Therapeutics Incorporated
CORT
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $12.1B
$111.62
▼ -1.05%
P/E
214.65
Mkt Cap
$12.1B
52-Wk Range
$28.66–$126.38
52-Week Range
$28.66 - $126.38
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cortisol-modulating technology platform
- First-mover advantage in selective cortisol modulation for multiple rare diseases
- Strong intellectual property portfolio protecting key pipeline candidates
- Clinical expertise in managing severe endocrine and metabolic disorders
Bear Case
2 risks
- Low volatility (beta 0.4).
- High premium - requires strong execution
Growth
Strong growth ahead
Expanding Korlym market penetration and label expansion
Value
High premium - requires strong execution
Momentum
Hot
+52.2% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying CORT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
JUL 29, 2026
Reported EPS of $0.36 vs $0.02 consensus (+1383.3% surprise). Revenue of $256.1M vs $221.1M expected (+15.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1383.3%
Revenue trend · last 8Q
—
—
—
+19%
+14%
+11%
+5%
+32%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$182.5M
$181.9M
$157.2M
$194.4M
$207.6M
$202.1M
$164.9M
$256.1M
Margins · last 8Q
Gross
98.4%
Operating
16.1%
Profit
16.4%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
0%
Sell
20%
Median Price Target
—
Latest: HC Wainwright · Jul 30, 2026
vs Industry
How CORT stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related